Transgenerational and intergenerational epigenetic inheritance in allergic diseases - 06/09/18
Abstract |
It has become clear that early life (including in utero exposures) is a key window of vulnerability during which environmental exposures can alter developmental trajectories and initiate allergic disease development. However, recent evidence suggests that there might be additional windows of vulnerability to environmental exposures in the parental generation before conception or even in previous generations. There is evidence suggesting that information of prior exposures can be transferred across generations, and experimental animal models suggest that such transmission can be conveyed through epigenetic mechanisms. Although the molecular mechanisms of intergenerational and transgenerationational epigenetic transmission have yet to be determined, the realization that environment before conception can alter the risks of allergic diseases has profound implications for the development of public health interventions to prevent disease. Future research in both experimental models and in multigenerational human cohorts is needed to better understand the role of intergenerational and transgenerational effects in patients with asthma and allergic disease. This will provide the knowledge basis for a new approach to efficient intervention strategies aimed at reducing the major public health challenge of these conditions.
Le texte complet de cet article est disponible en PDF.Key words : Transgenerational, intergenerational, multigenerational, parental, epigenetics, DNA methylation, asthma, allergy, environment
Abbreviations used : DNAm, miRNA, ncRNA, RHINESSA
Plan
Supported by the National Institutes of Health grants R01AI091905 and R01HL132321 (PI: Karmaus) and R01AI121226 (MPI: Zhang and Holloway), the Western Norway Health Authorities grant 912011, and the European Union (Horizon 2020, GA-633212) Ageing Lungs in European Cohorts study. |
|
Disclosure of potential conflict of interest: F. I. Rezwan is supported by the European Union (EU). W. Karmaus receives grant support from the University of Memphis and the National Institutes of Health (NIH). C. Svanes receives grant support from the Western Norway Health Authorities and EU. J. W. Holloway receives grant support from the MRC UK, NIH, and EU. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 3
P. 765-772 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?